Harrow announced the completion of the transfer to Harrow of the new drug application, or NDA, for Triesence 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. In January of 2023, Harrow agreed to acquire the U.S. commercial rights to Triesence. Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HROW:
- Harrow Health price target lowered to $30 from $45 at B. Riley
- Harrow Health price target lowered to $20 from $37 at Lake Street
- Harrow Health (NASDAQ:HROW) Plummets on Dismal Q3 Print
- Harrow Health reports Q3 core EPS (9c), consensus 5c
- Harrow Health options imply 15.4% move in share price post-earnings
